Profund Advisors LLC Acquires 56,597 Shares of Collegium Pharmaceutical, Inc. $COLL

Profund Advisors LLC increased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 621.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 65,710 shares of the specialty pharmaceutical company’s stock after purchasing an additional 56,597 shares during the period. Profund Advisors LLC owned approximately 0.20% of Collegium Pharmaceutical worth $1,434,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in COLL. PNC Financial Services Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 418 shares in the last quarter. Assetmark Inc. increased its stake in shares of Collegium Pharmaceutical by 9.3% in the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 335 shares in the last quarter. Allworth Financial LP acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at $175,000. EverSource Wealth Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 20.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,035 shares of the specialty pharmaceutical company’s stock valued at $167,000 after acquiring an additional 861 shares during the period. Finally, Vise Technologies Inc. acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter valued at $211,000.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on COLL shares. Truist Financial started coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price target for the company. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Barclays dropped their price objective on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $48.71.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $23.68 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical, Inc. has a twelve month low of $21.43 and a twelve month high of $50.79. The stock’s 50 day moving average is $23.23 and its 200-day moving average is $33.24. The firm has a market capitalization of $771.02 million, a price-to-earnings ratio of 3.33, a PEG ratio of 0.72 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. During the same period last year, the business earned $1.68 EPS. Collegium Pharmaceutical’s quarterly revenue was up 6.3% compared to the same quarter last year. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 6.42 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.